Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$738.00
-$6.50 (-0.9%)
Closing Price on November 22, 2024
REGN Articles
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday included Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, United Technologies and Vonage.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday included Activision Blizzard, BioMarin Pharmaceuticals, Ciena, Delta Air Lines, GlaxoSmithKline, Procter & Gamble, Regeneron...
Published:
Last Updated:
The included Achaogen, Apple, Athenahealth, Crocs, Finisar, Jabil, Michael Kors, Occidental Petroleum, Starbucks and Walt Disney.
Published:
Last Updated:
Thursday was a positive day for the broad U.S. markets. All three major indices recovered handily from Wednesday’s drop. Crude oil made a solid gain in the session. The S&P 500 sectors were...
Published:
Last Updated:
Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
Published:
Last Updated:
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis...
Published:
Last Updated:
Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients with wet age-related macular degeneration.
Published:
Last Updated:
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the top companies are starting to apply...
Published:
Last Updated:
Friday was a relatively positive day for the broad U.S. markets. Although crude oil backed off, it is still holding just above the $70 price level. The S&P 500 sectors were split down the middle.
Published:
Last Updated:
Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.
Published:
Last Updated:
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Alcoa, CEMEX, Comerica, Facebook, General Motors, Incyte, Proofpoint and Regeneron Pharmaceuticals.
Published:
Last Updated:
While chasing what portfolio managers own isn’t always the best idea, many people have made a lot of money by simply mimicking what legendary investors like Warren Buffett hold.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Capital One, Domino's, Home Depot, Mosaic, Regenron, Six Flags, U.S. Steel and Walmart.
Published:
Last Updated: